HKSE · 1177.HK
Sino Biopharmaceutical Limited
HK$4.82-HK$0.03 (-0.62%)
Sino Biopharmaceutical Limited’s quoted price sits in the lower half of its reported 52-week range, 35.56% below the high.
Loading market information…
HKSE · 6929.HK · HKD
Stock price, dividends, earnings
Quote as of Oct 30, 2026, 07:57 AM UTC. Cached market data; not a live quote.
One-year closing-price history · HKD. Historical prices are not a forecast.
OrbusNeich Medical Group Holdings Limited’s quoted price sits in the lower half of its reported 52-week range, 23.31% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
THE INCOME SIDE
OrbusNeich Medical Group Holdings Limited’s forward annual dividend is HK$0.32 per share, paid quarterly. The forward yield is 8.57% at the quoted price. Future payments can change.
Historical amounts are adjusted for stock splits. Understand ex-dividend and payment dates →
BEHIND THE RESULTS
OrbusNeich Medical Group Holdings Limited’s next earnings report is currently expected on Mar 11, 2027. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow OrbusNeich Medical Group Holdings Limited’s reporting calendar.
THE COMPANY BEHIND THE TICKER
OrbusNeich Medical Group Holdings Limited functions as an investment holding entity, specializing in the development, distribution, sales, and marketing of medical instruments tailored for treating coronary and peripheral vascular ailments. The company boasts a significant international presence, serving markets across Japan, Europe, the Middle East, Africa, the Asia Pacific region, the People's Republic of China, and the United States. Its product offerings encompass a range of essential devices, including semi-compliant and scoring balloons used for initial vessel preparation, coronary stents for implantation, non-compliant balloons designed for post-dilatation, and a variety of specialized catheters. This extensive portfolio of products addresses critical steps within percutaneous coronary intervention (PCI) and percutaneous transluminal angioplasty (PTA) procedures. Founded in 2001, the company is headquartered in Shatin, Hong Kong, and operates as a subsidiary of Harmony Tree Limited.
Latest available per-share figures in HKD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 10:06 PM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
Completed calendar years and any current-year payments shown separately. Current-year totals are incomplete until all payments are made.
See annual income at the current dividend rate.
Assumes the annual dividend stays unchanged. Payments follow the company’s schedule. Excludes taxes, fees and currency changes.
| HK$565.80M |
| Q4 2022 | Jun 30, 2023 | HK$0.24 | HK$637.89M-4.26% vs estimate |
|---|
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
HK$4.82-HK$0.03 (-0.62%)
Sino Biopharmaceutical Limited’s quoted price sits in the lower half of its reported 52-week range, 35.56% below the high.
HK$1.47-HK$0.08 (-5.16%)
LifeTech Scientific Corporation’s quoted price sits in the lower half of its reported 52-week range, 38.24% below the high.
HK$18.64-HK$0.58 (-3.02%)
Zylox-Tonbridge Medical Technology Co., Ltd.’s quoted price sits in the lower half of its reported 52-week range, 33.43% below the high.
HK$30.00+HK$0.36 (+1.21%)
Shanghai Kindly Medical Instruments Co., Ltd.’s quoted price sits in the lower half of its reported 52-week range, 27.54% below the high.
HK$13.15-HK$1.10 (-7.72%)
LEPU ScienTech Medical Technology (Shanghai) Co., Ltd.’s quoted price sits in the lower half of its reported 52-week range, 33.59% below the high.
HK$53.20+HK$0.25 (+0.47%)
Shanghai HeartCare Medical Technology Corporation Limited’s quoted price sits in the upper half of its reported 52-week range, 20.48% below the high.
HK$5.22-HK$0.36 (-6.37%)
Acotec Scientific Holdings Limited’s quoted price sits in the lower half of its reported 52-week range, 65.93% below the high.
HK$0.93-HK$0.04 (-3.63%)
Shanghai Bio-heart Biological Technology Co., Ltd.’s quoted price sits in the lower half of its reported 52-week range, 89.43% below the high.
